Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.
Martin A KatzmanXuemei WangDalia B WajsbrotMatthieu BoucherPublished in: Journal of psychopharmacology (Oxford, England) (2020)
Early improvement in symptom clusters significantly predicts symptomatic or functional remission at week 8 in patients with depression receiving desvenlafaxine (50 or 100 mg) or placebo. Importantly, patients without early improvement were less likely to remit.
Keyphrases
- end stage renal disease
- ejection fraction
- patient reported
- chronic kidney disease
- newly diagnosed
- prognostic factors
- depressive symptoms
- peritoneal dialysis
- double blind
- major depressive disorder
- randomized controlled trial
- placebo controlled
- phase iii
- clinical trial
- rheumatoid arthritis
- disease activity
- patient reported outcomes
- ulcerative colitis